LFG
IMDX

Larson Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Larson Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125
Closed -$383 – 3438
2025
Q1 		$383 Buy
+125
New +$338 ﹤0.01% 2644

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Larson Financial Group's IMDX Position: Q2 2025 in Review

Larson Financial Group sold out of Insight Molecular Diagnostics (IMDX) in Q2 2025, closing a stake of 125 shares — an estimated $383 sold.

Larson Financial Group first reported a position in IMDX in Q1 2025 and held it in 1 quarter. The position peaked at $383 in Q1 2025. 30 funds tracked by Wall St. Rank hold IMDX as of Q2 2025.

  • Larson Financial Group reported no remaining Insight Molecular Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Larson Financial Group sold 125 Insight Molecular Diagnostics shares in Q2 2025, an estimated $383.
  • Larson Financial Group first reported a position in Insight Molecular Diagnostics in Q1 2025 and held it in 1 quarter.
  • Larson Financial Group's Insight Molecular Diagnostics position peaked at $383 in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.